Medexus Pharmaceuticals Inc. (MDP.TO)
CAD 2.76
(-1.43%)
CAD 2.76
(-1.43%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 34.15 Million USD | 24.75% |
| 2022 | 27.37 Million USD | -31.24% |
| 2021 | 39.81 Million USD | 16.07% |
| 2020 | 34.3 Million USD | 19.87% |
| 2019 | 28.61 Million CAD | 69.62% |
| 2018 | 16.87 Million CAD | 401.35% |
| 2017 | 3.36 Million CAD | 3.79% |
| 2016 | 3.24 Million CAD | 7.62% |
| 2015 | 3.01 Million CAD | 6.6% |
| 2014 | 2.82 Million CAD | 60123.1% |
| 2013 | 4693.00 CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 30.26 Million USD | -11.39% |
| 2023 Q4 | 34.15 Million USD | -8.22% |
| 2023 Q1 | 25.44 Million USD | -7.08% |
| 2023 Q2 | 23.73 Million USD | -6.72% |
| 2023 Q3 | 37.21 Million USD | 56.81% |
| 2023 FY | 34.15 Million USD | 24.75% |
| 2022 Q1 | 37.94 Million USD | -4.69% |
| 2022 Q4 | 27.37 Million USD | 5556.4% |
| 2022 Q3 | 484 Thousand USD | -98.43% |
| 2022 FY | 27.37 Million USD | -31.24% |
| 2022 Q2 | 30.87 Million USD | -18.65% |
| 2021 Q2 | 34.53 Million USD | -2.26% |
| 2021 Q4 | 39.81 Million USD | 14.53% |
| 2021 Q3 | 34.76 Million USD | 0.68% |
| 2021 Q1 | 35.33 Million USD | 3.0% |
| 2021 FY | 39.81 Million USD | 16.07% |
| 2020 Q2 | 31.26 Million CAD | 4.47% |
| 2020 FY | 34.3 Million USD | 19.87% |
| 2020 Q3 | 33.54 Million CAD | 7.28% |
| 2020 Q4 | 34.3 Million USD | 2.26% |
| 2020 Q1 | 29.93 Million CAD | 4.6% |
| 2019 Q4 | 28.61 Million CAD | 44.35% |
| 2019 FY | 28.61 Million CAD | 69.62% |
| 2019 Q3 | 19.82 Million CAD | 5.15% |
| 2019 Q1 | 18.38 Million CAD | 8.95% |
| 2019 Q2 | 18.85 Million CAD | 2.58% |
| 2018 Q1 | 3.38 Million CAD | 0.73% |
| 2018 Q4 | 16.87 Million CAD | 2.92% |
| 2018 FY | 16.87 Million CAD | 401.35% |
| 2018 Q2 | 3.56 Million CAD | 5.03% |
| 2018 Q3 | 16.39 Million CAD | 360.41% |
| 2017 FY | 3.36 Million CAD | 3.79% |
| 2017 Q1 | 3.41 Million CAD | 5.36% |
| 2017 Q4 | 3.36 Million CAD | -10.02% |
| 2017 Q3 | 3.73 Million CAD | 1.54% |
| 2017 Q2 | 3.68 Million CAD | 7.82% |
| 2016 Q3 | 3.13 Million CAD | 0.34% |
| 2016 FY | 3.24 Million CAD | 7.62% |
| 2016 Q2 | 3.12 Million CAD | 0.87% |
| 2016 Q4 | 3.24 Million CAD | 3.48% |
| 2016 Q1 | 3.09 Million CAD | 2.75% |
| 2015 Q2 | 2.73 Million CAD | -6.44% |
| 2015 Q1 | 2.92 Million CAD | 3.35% |
| 2015 FY | 3.01 Million CAD | 6.6% |
| 2015 Q4 | 3.01 Million CAD | 12.62% |
| 2015 Q3 | 2.67 Million CAD | -2.12% |
| 2014 Q3 | 1292.15 CAD | -78.44% |
| 2014 Q2 | 5991.87 CAD | -16.42% |
| 2014 FY | 2.82 Million CAD | 60123.1% |
| 2014 Q1 | 7169.44 CAD | 0.0% |
| 2014 Q4 | 2.82 Million CAD | 218626.92% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2013 Q3 | 538.98 Thousand CAD | 0.0% |
| 2013 FY | 4693.00 CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q3 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Aurora Cannabis Inc. | 47.57 Million CAD | 28.211% |
| Avicanna Inc. | 95.36 Thousand CAD | -35714.056% |
| Avant Brands Inc. | 1.74 Million CAD | -1861.689% |
| Cardiol Therapeutics Inc. | 158.53 Thousand CAD | -21443.285% |
| Crescita Therapeutics Inc. | 815 Thousand CAD | -4090.552% |
| Knight Therapeutics Inc. | 44.01 Million CAD | 22.408% |
| MediPharm Labs Corp. | 69 Thousand CAD | -49397.101% |
| OrganiGram Holdings Inc. | 79 Thousand CAD | -43131.646% |
| Canopy Growth Corporation | 493.29 Million CAD | 93.077% |
| Willow Biosciences Inc. | 594 Thousand CAD | -5649.663% |
| Auxly Cannabis Group Inc. | 81.38 Million CAD | 58.034% |